{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:35:51Z","timestamp":1781818551790,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00219","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T04:18:40Z","timestamp":1529381920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Cancer Immunotherapy and the Immune Response in Follicular Lymphoma"],"prefix":"10.3389","volume":"8","author":[{"given":"Frank","family":"Stenner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.20020063","article-title":"Suppression of lymphoma and epithelial malignancies effected by interferon gamma","volume":"196","author":"Street","year":"2002","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1084\/jem.192.5.755","article-title":"Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma","volume":"192","author":"Smyth","year":"2000","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1182\/blood-2007-10-115915","article-title":"Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling","volume":"111","author":"Byers","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa\/Mayo clinic specialized program of research excellence molecular epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5581\/1516-8484.20120015","article-title":"Follicular lymphoma\u2014treatment and prognostic factors","volume":"34","author":"Luminari","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3960\/jslrt.54.3","article-title":"Pathology of follicular lymphoma","volume":"54","author":"Takata","year":"2014","journal-title":"J Clin Exp Hematop"},{"key":"B9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/asheducation-2007.1.216","article-title":"Clinical features, prognosis and treatment of follicular lymphoma","volume":"2007","author":"Salles","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1093\/annonc\/mdx020","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/cncr.29491","article-title":"What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?","volume":"121","author":"Vargo","year":"2015","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood.V128.22.464.464","article-title":"Targeting CD74 with novel antibody drug conjugates (ADCs) for the treatment of B-cell non-Hodgkin\u2019s lymphoma (NHL)","volume":"128","author":"Li","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1182\/blood.V128.22.4176.4176","article-title":"hLL2-Cys-PBD, a new site-specifically conjugated, pyrrolobenzodiazepine (PBD) dimer-based antibody drug conjugate (ADC) targeting CD22-expressing B-cell malignancies","volume":"128","author":"Zammarchi","year":"2016","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1158\/2326-6066.CIR-14-0125","article-title":"Afucosylated antibodies increase activation of Fc RIIIa-dependent signaling components to intensify processes promoting ADCC","volume":"3","author":"Liu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131 I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2017-04-779389","article-title":"Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies","volume":"130","author":"Ryan","year":"2017","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JOP.2017.026336","article-title":"Allogeneic transplantation for follicular lymphoma: does one size fit all?","volume":"13","author":"Hamadani","year":"2017","journal-title":"J Oncol Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8516","DOI":"10.1200\/jco.2015.33.15_suppl.8516","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"33","author":"Schuster","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00219\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T16:51:21Z","timestamp":1571503881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00219\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":31,"alternative-id":["10.3389\/fonc.2018.00219"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00219","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"article-number":"219"}}